[go: up one dir, main page]

SG11201902818PA - Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation - Google Patents

Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation

Info

Publication number
SG11201902818PA
SG11201902818PA SG11201902818PA SG11201902818PA SG11201902818PA SG 11201902818P A SG11201902818P A SG 11201902818PA SG 11201902818P A SG11201902818P A SG 11201902818PA SG 11201902818P A SG11201902818P A SG 11201902818PA SG 11201902818P A SG11201902818P A SG 11201902818PA
Authority
SG
Singapore
Prior art keywords
residue
amino acid
cyclic peptide
consecutive
antibody
Prior art date
Application number
SG11201902818PA
Inventor
Koichi Minami
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of SG11201902818PA publication Critical patent/SG11201902818PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282—Porous sorbents
    • B01J20/285—Porous sorbents based on polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

CYCLIC PEPTIDE, AFFINITY CHROMATOGRAPHY SUPPORT, LABELED ANTIBODY, ANTIBODY DRUG CONJUGATE, AND PHARMACEUTICAL PREPARATION A cyclic peptide is represented by Formula (I), RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC    (I) in Formula (I), RN represents an N-terminal group; RC represents a C-terminal group; X1 represents an L-leucine residue, an L-isoleucine residue, an L-methionine residue, an L-lysine residue, or an L-arginine residue; X2 represents an L-valine residue or an L-isoleucine residue; X3 represents an L-tryptophan residue or an L-phenylalanine residue; one of Xa and Xb represents an amino acid residue derived from an amino acid having an azide group on a side chain and the other represents an amino acid residue derived from an amino acid having an alkynyl group on a side chain,and Xg, Xh, Xi, Xj, Xm, and Xn each represent g consecutive X’s, consecutive i X’s, consecutive m X’s, n consecutive X’s; X represents an amino acid residue. [No Suitable Figure]
SG11201902818PA 2016-09-30 2017-08-17 Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation SG11201902818PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016194506 2016-09-30
JP2017116490 2017-06-14
PCT/JP2017/029517 WO2018061509A1 (en) 2016-09-30 2017-08-17 Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody-drug conjugate, and pharmaceutical preparation

Publications (1)

Publication Number Publication Date
SG11201902818PA true SG11201902818PA (en) 2019-05-30

Family

ID=61760423

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201902818PA SG11201902818PA (en) 2016-09-30 2017-08-17 Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation

Country Status (10)

Country Link
US (1) US11066446B2 (en)
EP (2) EP3521300A4 (en)
JP (1) JP6892867B2 (en)
KR (1) KR102243870B1 (en)
CN (1) CN109790202B (en)
BR (1) BR112019006301A2 (en)
CA (1) CA3036768A1 (en)
RU (1) RU2019109008A (en)
SG (1) SG11201902818PA (en)
WO (1) WO2018061509A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020210506B2 (en) * 2019-01-23 2025-02-13 AbTis Co., Ltd. Compound for preparation of antibody-payload conjugate and use thereof
CN116004221B (en) * 2022-12-15 2023-12-19 湖南卓润生物科技有限公司 New application of cyclic peptide, acridine labeled complex, preparation method and detection kit
CN117986328B (en) * 2024-04-03 2024-07-09 江西省转化医学研究院 Cyclic peptide luminescent coupling molecule and preparation method and application thereof
CN118033151B (en) * 2024-04-11 2024-06-18 江西省转化医学研究院 Homogeneous chemiluminescent procalcitonin detection reagent constructed by cyclopeptide luminescent coupling molecules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2002038592A2 (en) * 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptides, the production and use thereof for binding immunoglobulins
KR20040087765A (en) 2003-04-09 2004-10-15 주식회사 일산 Pipe forming method and the device
JP4997293B2 (en) * 2007-02-23 2012-08-08 エイルロン セラピューティクス，インコーポレイテッド Triazole macrocycle
EP2310407A4 (en) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
US9227995B2 (en) * 2010-04-23 2016-01-05 Øyvind Jacobsen Peptides
EP2678350A1 (en) 2011-02-22 2014-01-01 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
EP2749646B1 (en) * 2011-08-24 2018-03-21 Kagoshima University IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME
EP2604281B1 (en) * 2011-12-14 2014-07-30 Centre National de la Recherche Scientifique (CNRS) Clicked somatostatin conjugated analogs for biological applications
CN104395335A (en) 2012-02-08 2015-03-04 努艾利克斯德国股份有限公司 Ligands for antibody and fc-fusion protein purification by affinity chromotography iv
EP3010550B1 (en) * 2013-06-20 2021-10-27 California Institute of Technology Cyclic peptides as protein targeting agents
US10227383B2 (en) 2015-05-20 2019-03-12 Kagoshima University Specific modification of antibody with IgG-binding peptide
JP6554452B2 (en) * 2015-10-23 2019-07-31 富士フイルム株式会社 Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody drug complex, and pharmaceutical preparation
CN109983026B (en) * 2016-12-09 2023-09-19 富士胶片株式会社 Carrier for mixed mode affinity chromatography
JP6831903B2 (en) * 2017-03-21 2021-02-17 富士フイルム株式会社 Peptide compounds and methods for producing them, screening compositions, and methods for selecting peptide compounds.

Also Published As

Publication number Publication date
JP6892867B2 (en) 2021-06-23
CN109790202B (en) 2022-09-13
US20190202864A1 (en) 2019-07-04
KR20190039824A (en) 2019-04-15
RU2019109008A (en) 2020-10-30
EP3521300A4 (en) 2019-12-25
RU2019109008A3 (en) 2020-10-30
US11066446B2 (en) 2021-07-20
CA3036768A1 (en) 2018-04-05
KR102243870B1 (en) 2021-04-22
BR112019006301A2 (en) 2019-07-30
EP4043479A1 (en) 2022-08-17
CN109790202A (en) 2019-05-21
EP3521300A1 (en) 2019-08-07
WO2018061509A1 (en) 2018-04-05
JPWO2018061509A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
HRP20191254T1 (en) Cell penetrating peptides and methods of making and using thereof
SG11201902818PA (en) Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
CY1121658T1 (en) PEPTIDES AND THEIR USE
UA110473C2 (en) METHOD OF TREATMENT OF CANCER WITH TUMOR-ASSOCIATED ANTIGEN OBTAINED FROM CYCLINE D1
MY187741A (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
EA201990885A1 (en) COMPOSITIONS CONTAINING SHORT PEPTIDES OBTAINED FROM PEDF AND THEIR APPLICATION
CO6241137A2 (en) CXCR4 CYCLE PEPTIDE ANTAGONISTS
BR112017009790A2 (en) anti-ang2 antibodies and methods of use
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
RS53872B1 (en) Novel and powerful mhc-class ii peptides derived from survivin and neurocan
MX2020010806A (en) Anti-inflammatory peptides, and uses thereof.
IN2014DN03424A (en)
EA201892007A1 (en) 3-DESOXY DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS ON ITS BASIS
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
EP4374913A3 (en) Novel human serum albumin mutant
MX2022007881A (en) MUTANT F PROTEIN OF THE RESPIRATORY SYNCITIAL VIRUS (RSV) AND USES OF THE SAME.
EA201492068A1 (en) PEPTID HYDROCHLORIDE SALT AND ITS APPLICATION IN COMBINATION WITH OTHER PEPTIDES IN IMMUNOTHERAPY
CA3010982A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
ES2570458T3 (en) Peptidomimetics fixed on a matrix with modulating activity of CXCR7
IN2015DN03883A (en)
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
MX2010005816A (en) Stat3 epitope peptides.
NZ591133A (en) Novel melanoma antigen peptide and uses thereof